<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35052449</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13010109</ELocationID><Abstract><AbstractText>The recent advances in nucleic acid therapeutics demonstrate the potential to treat hereditary neurological disorders by targeting their causative genes. Spinal and bulbar muscular atrophy (SBMA) is an X-linked and adult-onset neurodegenerative disorder caused by the expansion of trinucleotide cytosine-adenine-guanine repeats, which encodes a polyglutamine tract in the <i>androgen receptor</i> gene. SBMA belongs to the family of polyglutamine diseases, in which the use of nucleic acids for silencing a disease-causing gene, such as antisense oligonucleotides and small interfering RNAs, has been intensively studied in animal models and clinical trials. A unique feature of SBMA is that both motor neuron and skeletal muscle pathology contribute to disease manifestations, including progressive muscle weakness and atrophy. As both motor neurons and skeletal muscles can be therapeutic targets in SBMA, nucleic acid-based approaches for other motor neuron diseases and myopathies may further lead to the development of a treatment for SBMA. Here, we review studies of nucleic acid-based therapeutic approaches in SBMA and related neurological disorders and discuss current limitations and perspectives to apply these approaches to patients with SBMA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirunagi</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Syowa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahashi</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Syowa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilleur</LastName><ForeName>Katherine G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Research and Clinical Development, Neuromuscular Development Unit, Biogen, 300, Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Syowa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Syowa-ku, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">nucleic acid therapeutics</Keyword><Keyword MajorTopicYN="N">polyglutamine disease</Keyword><Keyword MajorTopicYN="N">small interference RNA</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword></KeywordList><CoiStatement>K.G.M. is an employee of Biogen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35052449</ArticleId><ArticleId IdType="pmc">PMC8775157</ArticleId><ArticleId IdType="doi">10.3390/genes13010109</ArticleId><ArticleId IdType="pii">genes13010109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968;18:671&#x2013;680. doi: 10.1212/WNL.18.7.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2013;79. doi: 10.1038/352077a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352077a0</ArticleId><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A., Fischbeck K.H., Pennuto M., Fratta P., Katsuno M. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA) J. Neurol. Neurosurg. Psychiatry. 2020;91:1085&#x2013;1091. doi: 10.1136/jnnp-2020-322949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322949</ArticleId><ArticleId IdType="pubmed">32934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold F.J., Merry D.E. Molecular Mechanisms and Therapeutics for SBMA/Kennedy&#x2019;s Disease. Neurotherapeutics. 2019;16:928&#x2013;947. doi: 10.1007/s13311-019-00790-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks D.A., Johansen J.A., Mo K., Rao P., Eagleson B., Yu Z., Lieberman A.P., Breedlove S.M., Jordan C.L. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. USA. 2007;104:18259&#x2013;18264. doi: 10.1073/pnas.0705501104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705501104</ArticleId><ArticleId IdType="pmc">PMC2084330</ArticleId><ArticleId IdType="pubmed">17984063</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H., et al. Overexpression of IGF-1 in Muscle Attenuates Disease in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Neuron. 2009;63:316&#x2013;328. doi: 10.1016/j.neuron.2009.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.07.019</ArticleId><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes C.J., Ling S.C., Guo L.T., Hung G., Tsunemi T., Ly L., Tokunaga S., Lopez E., Sopher B.L., Bennett C.F., et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82:295&#x2013;307. doi: 10.1016/j.neuron.2014.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.03.001</ArticleId><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J.A., Witzigmann D., Thomson S.B., Chen S., Leavitt B.R., Cullis P.R., van der Meel R. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630&#x2013;643. doi: 10.1038/s41565-021-00898-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-021-00898-0</ArticleId><ArticleId IdType="pubmed">34059811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S.M., Aartsma-Rus A., Alves S., Borgos S.E., Buijsen R.A.M., Collin R.W.J., Covello G., Denti M.A., Desviat L.R., Echevarr&#xed;a L., et al. Delivery of oligonucleotide-based therapeutics: Challenges and opportunities. EMBO Mol. Med. 2021;13:1&#x2013;23. doi: 10.15252/emmm.202013243.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013243</ArticleId><ArticleId IdType="pmc">PMC8033518</ArticleId><ArticleId IdType="pubmed">33821570</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharner J., Aznarez I. Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics. Mol. Ther. 2021;29:540&#x2013;554. doi: 10.1016/j.ymthe.2020.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7854307</ArticleId><ArticleId IdType="pubmed">33359792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K., Katsuno M. Pathogenesis of Polyglutamine Diseases. eLS. 2018:1&#x2013;10. doi: 10.1002/9780470015902.a0021486.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470015902.a0021486.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Shakkottai V.G., Albin R.L. Polyglutamine Repeats in Neurodegenerative Diseases. Annu. Rev. Pathol. Mech. Dis. 2019;14:1&#x2013;27. doi: 10.1146/annurev-pathmechdis-012418-012857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012857</ArticleId><ArticleId IdType="pmc">PMC6387631</ArticleId><ArticleId IdType="pubmed">30089230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiszer A., Krzyzosiak W.J. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 2014;42:6787&#x2013;6810. doi: 10.1093/nar/gku385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku385</ArticleId><ArticleId IdType="pmc">PMC4066792</ArticleId><ArticleId IdType="pubmed">24848018</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser M.S., Kordasiewicz H.B., McBride J.L. Gene suppression strategies for dominantly inherited neurodegenerative diseases: Lessons from Huntington&#x2019;s disease and spinocerebellar ataxia. Hum. Mol. Genet. 2016;25:R53&#x2013;R64. doi: 10.1093/hmg/ddv442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv442</ArticleId><ArticleId IdType="pmc">PMC4802374</ArticleId><ArticleId IdType="pubmed">26503961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Alegre P. Recent advances in molecular therapies for neurological disease: Triplet repeat disorders. Hum. Mol. Genet. 2019;28:R80&#x2013;R87. doi: 10.1093/hmg/ddz138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz138</ArticleId><ArticleId IdType="pmc">PMC6796999</ArticleId><ArticleId IdType="pubmed">31227833</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva A.C., Lobo D.D., Martins I.M., Lopes S.M., Henriques C., Duarte S.P., Dodart J.-C., Nobre R.J., Pereira de Almeida L. Antisense oligonucleotide therapeutics in neurodegenerative diseases: The case of polyglutamine disorders. Brain. 2019;143:407&#x2013;429. doi: 10.1093/brain/awz328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz328</ArticleId><ArticleId IdType="pubmed">31738395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi S.J., Leavitt B.R., Landwehrmeyer G.B., Wild E.J., Saft C., Barker R.A., Blair N.F., Craufurd D., Priller J., Rickards H., et al. Targeting Huntingtin Expression in Patients with Huntington&#x2019;s Disease. N. Engl. J. Med. 2019;380:2307&#x2013;2316. doi: 10.1056/NEJMoa1900907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1900907</ArticleId><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon D. Failure of genetic therapies for Huntington&#x2019;s devastates community. Nature. 2021;593:180. doi: 10.1038/d41586-021-01177-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01177-7</ArticleId><ArticleId IdType="pubmed">33963316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Discov. 2021;20:412&#x2013;413. doi: 10.1038/d41573-021-00088-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00088-6</ArticleId><ArticleId IdType="pubmed">34012000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitler B., Froelich S., Marlen K., Shivak D.A., Yu Q., Li D., Pearl J.R., Miller J.C., Zhang L., Paschon D.E., et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington&#x2019;s disease. Nat. Med. 2019;25:1131&#x2013;1142. doi: 10.1038/s41591-019-0478-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0478-3</ArticleId><ArticleId IdType="pubmed">31263285</ArticleId></ArticleIdList></Reference><Reference><Citation>Alterman J.F., Godinho B.M.D.C., Hassler M.R., Ferguson C.M., Echeverria D., Sapp E., Haraszti R.A., Coles A.H., Conroy F., Miller R., et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat. Biotechnol. 2019;37:884&#x2013;894. doi: 10.1038/s41587-019-0205-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0205-0</ArticleId><ArticleId IdType="pmc">PMC6879195</ArticleId><ArticleId IdType="pubmed">31375812</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga C.A., Swoboda K.J., Darras B.T., Iannaccone S.T., Montes J., De Vivo D.C., Norris D.A., Bennett C.F., Bishop K.M. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology. 2016;86:890&#x2013;897. doi: 10.1212/WNL.0000000000002445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002445</ArticleId><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M., Iannaccone S.T., Kirschner J., Kuntz N.L., Saito K., et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2018;378:625&#x2013;635. doi: 10.1056/NEJMoa1710504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., Le T.T., Morales P.R., Rich M.M., Burghes A.H.M., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 2010;28:271&#x2013;274. doi: 10.1038/nbt.1610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1610</ArticleId><ArticleId IdType="pmc">PMC2889698</ArticleId><ArticleId IdType="pubmed">20190738</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1713&#x2013;1722. doi: 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Day J.W., Finkel R.S., Chiriboga C.A., Connolly A.M., Crawford T.O., Darras B.T., Iannaccone S.T., Kuntz N.L., Pe&#xf1;a L.D.M., Shieh P.B., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284&#x2013;293. doi: 10.1016/S1474-4422(21)00001-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00001-6</ArticleId><ArticleId IdType="pubmed">33743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E., Muntoni F., Baranello G., Masson R., Boespflug-Tanguy O., Bruno C., Corti S., Daron A., Deconinck N., Servais L., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832&#x2013;841. doi: 10.1016/S1474-4422(21)00251-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00251-9</ArticleId><ArticleId IdType="pubmed">34536405</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen G., Burghes A.H.M., Hsieh C., Do J., Chu B.T.T., Perry S., Barkho B., Kaufmann P., Sproule D.M., Feltner D.E., et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat. Med. 2021;27 doi: 10.1038/s41591-021-01483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01483-7</ArticleId><ArticleId IdType="pubmed">34608334</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen Announces Topline Results from the Tofersen Phase 3 Study and Its Open-Label Extension in SOD1-ALS.  [(accessed on 4 December 2021)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its.</Citation></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene therapy for ALS: A review. Mol. Ther. 2021;29:14&#x2013;17. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord. 2002;12:926&#x2013;929. doi: 10.1016/S0960-8966(02)00140-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8966(02)00140-2</ArticleId><ArticleId IdType="pubmed">12467747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrpant C., Adams A.M., Meloni P.L., Muntoni F., Fletcher S., Wilton S.D. Rational design of antisense oligomers to induce dystrophin exon skipping. Mol. Ther. 2009;17:1418&#x2013;1426. doi: 10.1038/mt.2009.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.49</ArticleId><ArticleId IdType="pmc">PMC2835229</ArticleId><ArticleId IdType="pubmed">19293776</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein C.A. Eteplirsen approved for duchenne muscular dystrophy: The FDA faces a difficult choice. Mol. Ther. 2016;24:1884&#x2013;1885. doi: 10.1038/mt.2016.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.188</ArticleId><ArticleId IdType="pmc">PMC5154484</ArticleId><ArticleId IdType="pubmed">27916994</ArticleId></ArticleIdList></Reference><Reference><Citation>Aartsma-Rus A., Krieg A.M. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017;27:1&#x2013;3. doi: 10.1089/nat.2016.0657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2016.0657</ArticleId><ArticleId IdType="pmc">PMC5312460</ArticleId><ArticleId IdType="pubmed">27929755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasfaout H., Buono S., Guo S., Kretz C., Messaddeq N., Booten S., Greenlee S., Monia B.P., Cowling B.S., Laporte J. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat. Commun. 2017;8:15661. doi: 10.1038/ncomms15661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15661</ArticleId><ArticleId IdType="pmc">PMC5467247</ArticleId><ArticleId IdType="pubmed">28589938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim K.R.Q., Maruyama R., Echigoya Y., Nguyen Q., Zhang A., Khawaja H., Chandra S.S., Jones T., Jones P., Chen Y.W., et al. Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proc. Natl. Acad. Sci. USA. 2020;117:16509&#x2013;16515. doi: 10.1073/pnas.1909649117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1909649117</ArticleId><ArticleId IdType="pmc">PMC7368245</ArticleId><ArticleId IdType="pubmed">32601200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S.A., Rodino-Klapac L.R., Goodspeed K., Gray S.J., Kay C.N., Boye S.L., Boye S.E., George L.A., Salabarria S., et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol. Ther. 2021;29:464&#x2013;488. doi: 10.1016/j.ymthe.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7854298</ArticleId><ArticleId IdType="pubmed">33309881</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher D.R., Thapa K., Dharia S.D., Khan N., Potter R.A., Rodino-Klapac L.R., Mendell J.R. Clinical development on the frontier: Gene therapy for duchenne muscular dystrophy. Expert Opin. Biol. Ther. 2020;20:263&#x2013;274. doi: 10.1080/14712598.2020.1725469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2020.1725469</ArticleId><ArticleId IdType="pubmed">32031420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Sahenk Z., Lehman K., Nease C., Lowes L.P., Miller N.F., Iammarino M.A., Alfano L.N., Nicholl A., Al-Zaidy S., et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020;77:1122&#x2013;1131. doi: 10.1001/jamaneurol.2020.1484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1484</ArticleId><ArticleId IdType="pmc">PMC7296461</ArticleId><ArticleId IdType="pubmed">32539076</ArticleId></ArticleIdList></Reference><Reference><Citation>Laporte J., Hu L.J., Kretz C., Mandel J.L., Kioschis P., Coy J.F., Klauck S.M., Poustka A., Dahl N. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 1996;13:175&#x2013;182. doi: 10.1038/ng0696-175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0696-175</ArticleId><ArticleId IdType="pubmed">8640223</ArticleId></ArticleIdList></Reference><Reference><Citation>Beggs A.H., Byrne B.J., De Chastonay S., Haselkorn T., Hughes I., James E.S., Kuntz N.L., Simon J., Swanson L.C., Yang M.L., et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy: The recensus study. Muscle Nerve. 2018;57:550&#x2013;560. doi: 10.1002/mus.26018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26018</ArticleId><ArticleId IdType="pmc">PMC5900738</ArticleId><ArticleId IdType="pubmed">29149770</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippidis A. Fourth Boy Dies in Clinical Trial of Astellas&#x2019; AT132. Hum. Gene Ther. 2021;32:1008&#x2013;1010. doi: 10.1089/hum.2021.29182.bfs.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2021.29182.bfs</ArticleId><ArticleId IdType="pubmed">34662231</ArticleId></ArticleIdList></Reference><Reference><Citation>Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy.  [(accessed on 4 December 2021)].  Available online:  https://www.astellas.com/en/news/17161.</Citation></Reference><Reference><Citation>Sahashi K., Katsuno M., Hung G., Adachi H., Kondo N., Nakatsuji H., Tohnai G., Iida M., Bennett F.F., Sobue G. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2015;24:5985&#x2013;5994. doi: 10.1093/hmg/ddv300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv300</ArticleId><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Yu Z., Murray S., Peralta R., Low A., Guo S., Yu X.X., Cortes C.J., Bennett C.F., Monia B.P., et al. Peripheral Androg en Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy. Cell Rep. 2014;7:774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirunagi T., Sahashi K., Tachikawa K., Leu A.I., Nguyen M., Mukthavaram R., Karmali P.P., Chivukula P., Tohnai G., Iida M., et al. Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS. Mol. Ther. Nucleic Acids. 2021;24:1&#x2013;10. doi: 10.1016/j.omtn.2021.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2021.02.007</ArticleId><ArticleId IdType="pmc">PMC7937577</ArticleId><ArticleId IdType="pubmed">33738134</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki Y., Adachi H., Katsuno M., Minamiyama M., Jiang Y.-M., Huang Z., Doi H., Matsumoto S., Kondo N., Iida M., et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat. Med. 2012;18:1136&#x2013;1141. doi: 10.1038/nm.2791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2791</ArticleId><ArticleId IdType="pubmed">22660636</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourshafie N., Lee P.R., Chen K.L., Harmison G.G., Bott L.C., Katsuno M., Sobue G., Burnett B.G., Fischbeck K.H., Rinaldi C. MIR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy. Mol. Ther. 2016;24:937&#x2013;945. doi: 10.1038/mt.2016.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.13</ArticleId><ArticleId IdType="pmc">PMC4881766</ArticleId><ArticleId IdType="pubmed">26755334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W.F., Forouhan M., Roberts T.C., Dabney J., Ellerington R., Speciale A.A., Manzano R., Lieto M., Sangha G., Banerjee S., et al. Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. Sci. Adv. 2021;7:eabi6896. doi: 10.1126/sciadv.abi6896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abi6896</ArticleId><ArticleId IdType="pmc">PMC8378820</ArticleId><ArticleId IdType="pubmed">34417184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Liu J., Corey D.R. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol. 2010;17:1183&#x2013;1188. doi: 10.1016/j.chembiol.2010.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2010.10.013</ArticleId><ArticleId IdType="pmc">PMC3021381</ArticleId><ArticleId IdType="pubmed">21095568</ArticleId></ArticleIdList></Reference><Reference><Citation>Benizri S., Gissot A., Martin A., Vialet B., Grinstaff M.W., Barth&#xe9;l&#xe9;my P. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications. Bioconjug. Chem. 2019;30:366&#x2013;383. doi: 10.1021/acs.bioconjchem.8b00761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00761</ArticleId><ArticleId IdType="pmc">PMC6766081</ArticleId><ArticleId IdType="pubmed">30608140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T., Dwyer C.A., Yoshida-Tanaka K., Ihara K., Ohyagi M., Kaburagi H., Miyata H., Ebihara S., Yoshioka K., Ishii T., et al. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood&#x2013;brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol. 2021;39:1529&#x2013;1536. doi: 10.1038/s41587-021-00972-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00972-x</ArticleId><ArticleId IdType="pubmed">34385691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugo T., Terada M., Oikawa T., Miyata K., Nishimura S., Kenjo E., Ogasawara-Shimizu M., Makita Y., Imaichi S., Murata S., et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J. Control. Release. 2016;237:1&#x2013;13. doi: 10.1016/j.jconrel.2016.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.06.036</ArticleId><ArticleId IdType="pubmed">27369865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Zhang Y., Yang X., Hao C., Duan H. Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions. Front. Mol. Neurosci. 2021;14:618171. doi: 10.3389/fnmol.2021.618171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.618171</ArticleId><ArticleId IdType="pmc">PMC8236824</ArticleId><ArticleId IdType="pubmed">34194298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamori M., Panigrahi G.B., Lanni S., Gall-Duncan T., Hayakawa H., Tanaka H., Luo J., Otabe T., Li J., Sakata A., et al. A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nat. Genet. 2020;52:146&#x2013;159. doi: 10.1038/s41588-019-0575-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0575-8</ArticleId><ArticleId IdType="pmc">PMC7043212</ArticleId><ArticleId IdType="pubmed">32060489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>